Clinical trial
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic…
NCT00084630 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00084630 |
|---|---|
| Title | Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans |
| Official title | A Phase II Study of Imatinib (NSC-716051) in Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Fibrosarcoma, Dermatofibrosarcoma Protuberans, Recurrent Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma |
| Intervention type | Drug, Other |
| Interventions | imatinib mesylate, laboratory biomarker analysis |
| Enrollment | 40 |
| Start date | May 1, 2004 |
| Primary completion | Jul 1, 2007 |
| First posted | Jun 11, 2004 |
| Last update posted | Feb 28, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: